View ValuationAntibiotice 将来の成長Future 基準チェック /06現在、 Antibioticeの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長10.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Apr 01New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (7.8% net profit margin).Reported Earnings • Mar 30Full year 2025 earnings released: EPS: RON0.077 (vs RON0.15 in FY 2024)Full year 2025 results: EPS: RON0.077 (down from RON0.15 in FY 2024). Revenue: RON660.3m (down 4.1% from FY 2024). Net income: RON51.8m (down 49% from FY 2024). Profit margin: 7.8% (down from 15% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 27Antibiotice S.A. announces Annual dividend, payable on October 21, 2026Antibiotice S.A. announced Annual dividend of RON 0.0199 per share payable on October 21, 2026, ex-date on October 01, 2026 and record date on October 02, 2026.お知らせ • Jan 16+ 5 more updatesAntibiotice S.A. to Report Q1, 2026 Results on May 27, 2026Antibiotice S.A. announced that they will report Q1, 2026 results on May 27, 2026Reported Earnings • Nov 15Third quarter 2025 earnings released: RON0.025 loss per share (vs RON0.021 profit in 3Q 2024)Third quarter 2025 results: RON0.025 loss per share (down from RON0.021 profit in 3Q 2024). Revenue: RON137.2m (down 13% from 3Q 2024). Net loss: RON16.5m (down 220% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Sep 18Upcoming dividend of RON0.021 per shareEligible shareholders must have bought the stock before 25 September 2025. Payment date: 08 October 2025. Payout ratio is a comfortable 16% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Romanian dividend payers (6.3%). Lower than average of industry peers (2.9%).New Risk • Aug 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: RON0.039 (vs RON0.055 in 2Q 2024)Second quarter 2025 results: EPS: RON0.039 (down from RON0.055 in 2Q 2024). Revenue: RON175.8m (up 1.8% from 2Q 2024). Net income: RON26.5m (down 28% from 2Q 2024). Profit margin: 15% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 362% over the past three years.Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.11, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 309% over the past three years.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). GM, General Director & Chairman Ioan Nani is the most experienced director on the board, commencing their role in 2009. Non Independent Director Ionut-Sebastian Iavor was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.分析記事 • Apr 25Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last YearAntibiotice S.A.'s ( BVB:ATB ) dividend is being reduced by 75% to RON0.0206 per share on 8th of October, in comparison...分析記事 • Apr 04Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last YearThe board of Antibiotice S.A. ( BVB:ATB ) has announced that the dividend on 8th of October will be reduced by 75% from...Declared Dividend • Apr 03Dividend reduced to RON0.021Dividend of RON0.021 is 75% lower than last year. Ex-date: 25th September 2025 Payment date: 8th October 2025 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (60% earnings payout ratio) but not covered by cash flows (127% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 26% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.New Risk • Mar 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 150% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 150% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (127% cash payout ratio).Reported Earnings • Mar 02Full year 2024 earnings released: EPS: RON0.15 (vs RON0.12 in FY 2023)Full year 2024 results: EPS: RON0.15 (up from RON0.12 in FY 2023). Revenue: RON688.9m (up 12% from FY 2023). Net income: RON99.4m (up 23% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 25Antibiotice S.A., Annual General Meeting, Mar 28, 2025Antibiotice S.A., Annual General Meeting, Mar 28, 2025, at 10:00 E. Europe Standard Time. Location: at the company`s headquarters in the municipality, of iasi, str. valea lupului nr. 1, Romania分析記事 • Nov 23Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 3.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (156% cash payout ratio). Share price has been volatile over the past 3 months (3.5% average weekly change).Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to RON2.76, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 405% over the past three years.Upcoming Dividend • Sep 16Upcoming dividend of RON0.083 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 11 October 2024. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 2.7%. Lower than top quartile of Romanian dividend payers (7.0%). Higher than average of industry peers (2.2%).Reported Earnings • Aug 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON172.7m (up 22% from 2Q 2023). Net income: RON36.9m (down 7.3% from 2Q 2023). Profit margin: 21% (down from 28% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Romanian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Aug 05Now 20% undervaluedOver the last 90 days, the stock has risen 36% to RON2.67. The fair value is estimated to be RON3.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 49%.Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to RON3.14, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 475% over the past three years.分析記事 • Jun 07Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price BoostDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 25% in the...New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.49, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 351% over the past three years.Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.056 (vs RON0.033 in 1Q 2023)First quarter 2024 results: EPS: RON0.056 (up from RON0.033 in 1Q 2023). Revenue: RON186.0m (up 2.2% from 1Q 2023). Net income: RON37.3m (up 68% from 1Q 2023). Profit margin: 20% (up from 12% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 52% per year.Reported Earnings • Apr 22Full year 2023 earnings released: EPS: RON0.12 (vs RON0.077 in FY 2022)Full year 2023 results: EPS: RON0.12 (up from RON0.077 in FY 2022). Revenue: RON615.3m (up 22% from FY 2022). Net income: RON81.1m (up 57% from FY 2022). Profit margin: 13% (up from 10% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non Executive Chairman Lucian Timofticiuc was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 296% Dividend yield: 2.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (296% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change).分析記事 • Jan 30Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price JumpDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 26% in the...お知らせ • Jan 30+ 5 more updatesAntibiotice S.A. to Report Fiscal Year 2023 Results on Feb 28, 2024Antibiotice S.A. announced that they will report fiscal year 2023 results on Feb 28, 2024Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.64, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 238% over the past three years.分析記事 • Jan 13We Think Antibiotice (BVB:ATB) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.022 (vs RON0.009 in 3Q 2022)Third quarter 2023 results: EPS: RON0.022 (up from RON0.009 in 3Q 2022). Revenue: RON150.7m (up 28% from 3Q 2022). Net income: RON14.7m (up 133% from 3Q 2022). Profit margin: 9.8% (up from 5.4% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to RON1.39, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 189% over the past three years.Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.02, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 97% over the past three years.分析記事 • Aug 16These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt SafelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jan 17+ 4 more updatesAntibiotice S.A. to Report Fiscal Year 2022 Results on Feb 24, 2023Antibiotice S.A. announced that they will report fiscal year 2022 results on Feb 24, 2023Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM, Vice Chairman & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 12Third quarter 2021 earnings released: RON0.002 loss per share (vs RON0.002 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses were not reduced. Third quarter 2021 results: Revenue: RON122.4m (up 108% from 3Q 2020). Net loss: RON1.10m (flat on 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Jul 28Second quarter 2021 earnings released: EPS RON0.023 (vs RON0.022 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: RON121.5m (up 61% from 2Q 2020). Net income: RON15.3m (up 1.5% from 2Q 2020). Profit margin: 13% (down from 20% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.分析記事 • Jun 08Is Antibiotice (BVB:ATB) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • May 14First quarter 2021 earnings released: EPS RON0.006 (vs RON0.006 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON82.3m (up 10% from 1Q 2020). Net income: RON4.04m (down 1.0% from 1Q 2020). Profit margin: 4.9% (down from 5.5% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.分析記事 • Mar 10These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt ExtensivelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Feb 28Full year 2020 earnings released: EPS RON0.037 (vs RON0.046 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: RON382.8m (down 3.1% from FY 2019). Net income: RON25.1m (down 19% from FY 2019). Profit margin: 6.5% (down from 7.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.分析記事 • Feb 11Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend YieldToday we'll take a closer look at Antibiotice S.A. ( BVB:ATB ) from a dividend investor's perspective. Owning a strong...Is New 90 Day High Low • Jan 27New 90-day high: RON0.52The company is up 4.0% from its price of RON0.49 on 29 October 2020. The Romanian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period.分析記事 • Jan 12Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)Does the January share price for Antibiotice S.A. ( BVB:ATB ) reflect what it's really worth? Today, we will estimate...分析記事 • Dec 16Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory...分析記事 • Nov 24Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Nov 20New 90-day low: RON0.49The company is down 9.0% from its price of RON0.54 on 21 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: RON0.002 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: RON87.6m (up 23% from 3Q 2019). Net loss: RON1.10m (loss widened 46% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.Is New 90 Day High Low • Sep 18New 90-day low: RON0.52The company is down 3.0% from its price of RON0.53 on 19 June 2020. The Romanian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Antibiotice は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BVB:ATB - アナリストの将来予測と過去の財務データ ( )RON Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202566052-7072N/A9/30/202564957-14350N/A6/30/202567087-1238N/A3/31/202566798-5261N/A12/31/2024689102-2195N/A9/30/20246589244141N/A6/30/20246519334138N/A3/31/20246199626128N/A12/31/20236158124122N/A9/30/2023605991549N/A6/30/2023572794071N/A3/31/2023556653476N/A12/31/20225055171116N/A9/30/20224984162137N/A6/30/20224674547112N/A3/31/2022440354781N/A12/31/2021379301544N/A9/30/2021394273161N/A6/30/2021366272660N/A3/31/2021342264281N/A12/31/2020347264694N/A9/30/202035727-556N/A6/30/202037028-2645N/A3/31/202040332-5319N/A12/31/201939531-4921N/A9/30/201937135N/A61N/A6/30/201938537N/A59N/A3/31/201937534N/AN/AN/A12/31/201836934N/A21N/A9/30/201834834N/AN/AN/A6/30/201835134N/A9N/A3/31/201834432N/AN/AN/A12/31/201733934N/A19N/A9/30/201734433N/AN/AN/A6/30/201734133N/A28N/A3/31/201733829N/AN/AN/A12/31/201633730N/A3N/A9/30/201634330N/AN/AN/A6/30/201634528N/A45N/A3/31/201633628N/AN/AN/A12/31/201533427N/A60N/A9/30/201532125N/AN/AN/A6/30/201530528N/A34N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ATBの予測収益成長が 貯蓄率 ( 6.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ATBの収益がRO市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ATBの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ATBの収益がRO市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ATBの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ATBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 04:07終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Antibiotice S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Vladimira UrbankovaErste Group Bank AGAlex DodoiSSIF BRK Financial Group S.A.
New Risk • Apr 01New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (7.8% net profit margin).
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: RON0.077 (vs RON0.15 in FY 2024)Full year 2025 results: EPS: RON0.077 (down from RON0.15 in FY 2024). Revenue: RON660.3m (down 4.1% from FY 2024). Net income: RON51.8m (down 49% from FY 2024). Profit margin: 7.8% (down from 15% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 27Antibiotice S.A. announces Annual dividend, payable on October 21, 2026Antibiotice S.A. announced Annual dividend of RON 0.0199 per share payable on October 21, 2026, ex-date on October 01, 2026 and record date on October 02, 2026.
お知らせ • Jan 16+ 5 more updatesAntibiotice S.A. to Report Q1, 2026 Results on May 27, 2026Antibiotice S.A. announced that they will report Q1, 2026 results on May 27, 2026
Reported Earnings • Nov 15Third quarter 2025 earnings released: RON0.025 loss per share (vs RON0.021 profit in 3Q 2024)Third quarter 2025 results: RON0.025 loss per share (down from RON0.021 profit in 3Q 2024). Revenue: RON137.2m (down 13% from 3Q 2024). Net loss: RON16.5m (down 220% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Sep 18Upcoming dividend of RON0.021 per shareEligible shareholders must have bought the stock before 25 September 2025. Payment date: 08 October 2025. Payout ratio is a comfortable 16% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Romanian dividend payers (6.3%). Lower than average of industry peers (2.9%).
New Risk • Aug 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 17Second quarter 2025 earnings released: EPS: RON0.039 (vs RON0.055 in 2Q 2024)Second quarter 2025 results: EPS: RON0.039 (down from RON0.055 in 2Q 2024). Revenue: RON175.8m (up 1.8% from 2Q 2024). Net income: RON26.5m (down 28% from 2Q 2024). Profit margin: 15% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 362% over the past three years.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.11, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 309% over the past three years.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (4 non-independent directors). GM, General Director & Chairman Ioan Nani is the most experienced director on the board, commencing their role in 2009. Non Independent Director Ionut-Sebastian Iavor was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
分析記事 • Apr 25Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last YearAntibiotice S.A.'s ( BVB:ATB ) dividend is being reduced by 75% to RON0.0206 per share on 8th of October, in comparison...
分析記事 • Apr 04Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last YearThe board of Antibiotice S.A. ( BVB:ATB ) has announced that the dividend on 8th of October will be reduced by 75% from...
Declared Dividend • Apr 03Dividend reduced to RON0.021Dividend of RON0.021 is 75% lower than last year. Ex-date: 25th September 2025 Payment date: 8th October 2025 Dividend yield will be 0.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (60% earnings payout ratio) but not covered by cash flows (127% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 26% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
New Risk • Mar 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 150% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 150% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (127% cash payout ratio).
Reported Earnings • Mar 02Full year 2024 earnings released: EPS: RON0.15 (vs RON0.12 in FY 2023)Full year 2024 results: EPS: RON0.15 (up from RON0.12 in FY 2023). Revenue: RON688.9m (up 12% from FY 2023). Net income: RON99.4m (up 23% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 25Antibiotice S.A., Annual General Meeting, Mar 28, 2025Antibiotice S.A., Annual General Meeting, Mar 28, 2025, at 10:00 E. Europe Standard Time. Location: at the company`s headquarters in the municipality, of iasi, str. valea lupului nr. 1, Romania
分析記事 • Nov 23Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 3.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (156% cash payout ratio). Share price has been volatile over the past 3 months (3.5% average weekly change).
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to RON2.76, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 405% over the past three years.
Upcoming Dividend • Sep 16Upcoming dividend of RON0.083 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 11 October 2024. Payout ratio is a comfortable 60% and this is well supported by cash flows. Trailing yield: 2.7%. Lower than top quartile of Romanian dividend payers (7.0%). Higher than average of industry peers (2.2%).
Reported Earnings • Aug 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: RON172.7m (up 22% from 2Q 2023). Net income: RON36.9m (down 7.3% from 2Q 2023). Profit margin: 21% (down from 28% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Romanian stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Aug 05Now 20% undervaluedOver the last 90 days, the stock has risen 36% to RON2.67. The fair value is estimated to be RON3.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 49%.
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 21%After last week's 21% share price gain to RON3.14, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 475% over the past three years.
分析記事 • Jun 07Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price BoostDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 25% in the...
New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Romanian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to RON2.49, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 351% over the past three years.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: RON0.056 (vs RON0.033 in 1Q 2023)First quarter 2024 results: EPS: RON0.056 (up from RON0.033 in 1Q 2023). Revenue: RON186.0m (up 2.2% from 1Q 2023). Net income: RON37.3m (up 68% from 1Q 2023). Profit margin: 20% (up from 12% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 52% per year.
Reported Earnings • Apr 22Full year 2023 earnings released: EPS: RON0.12 (vs RON0.077 in FY 2022)Full year 2023 results: EPS: RON0.12 (up from RON0.077 in FY 2022). Revenue: RON615.3m (up 22% from FY 2022). Net income: RON81.1m (up 57% from FY 2022). Profit margin: 13% (up from 10% in FY 2022). The increase in margin was driven by higher revenue. Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 05Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non Executive Chairman Lucian Timofticiuc was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 21New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Cash payout ratio: 296% Dividend yield: 2.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (296% cash payout ratio). Share price has been volatile over the past 3 months (5.3% average weekly change).
分析記事 • Jan 30Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price JumpDespite an already strong run, Antibiotice S.A. ( BVB:ATB ) shares have been powering on, with a gain of 26% in the...
お知らせ • Jan 30+ 5 more updatesAntibiotice S.A. to Report Fiscal Year 2023 Results on Feb 28, 2024Antibiotice S.A. announced that they will report fiscal year 2023 results on Feb 28, 2024
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.64, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 238% over the past three years.
分析記事 • Jan 13We Think Antibiotice (BVB:ATB) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: RON0.022 (vs RON0.009 in 3Q 2022)Third quarter 2023 results: EPS: RON0.022 (up from RON0.009 in 3Q 2022). Revenue: RON150.7m (up 28% from 3Q 2022). Net income: RON14.7m (up 133% from 3Q 2022). Profit margin: 9.8% (up from 5.4% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to RON1.39, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 189% over the past three years.
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to RON1.02, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 25x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 97% over the past three years.
分析記事 • Aug 16These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt SafelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jan 17+ 4 more updatesAntibiotice S.A. to Report Fiscal Year 2022 Results on Feb 24, 2023Antibiotice S.A. announced that they will report fiscal year 2022 results on Feb 24, 2023
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM, Vice Chairman & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. GM & Non-Independent Executive Director Ioan Nani is the most experienced director on the board, commencing their role in 2009. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 12Third quarter 2021 earnings released: RON0.002 loss per share (vs RON0.002 loss in 3Q 2020)The company reported a solid third quarter result with improved revenues and control over costs, although losses were not reduced. Third quarter 2021 results: Revenue: RON122.4m (up 108% from 3Q 2020). Net loss: RON1.10m (flat on 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Jul 28Second quarter 2021 earnings released: EPS RON0.023 (vs RON0.022 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: RON121.5m (up 61% from 2Q 2020). Net income: RON15.3m (up 1.5% from 2Q 2020). Profit margin: 13% (down from 20% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
分析記事 • Jun 08Is Antibiotice (BVB:ATB) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • May 14First quarter 2021 earnings released: EPS RON0.006 (vs RON0.006 in 1Q 2020)The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: RON82.3m (up 10% from 1Q 2020). Net income: RON4.04m (down 1.0% from 1Q 2020). Profit margin: 4.9% (down from 5.5% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
分析記事 • Mar 10These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt ExtensivelyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Feb 28Full year 2020 earnings released: EPS RON0.037 (vs RON0.046 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: RON382.8m (down 3.1% from FY 2019). Net income: RON25.1m (down 19% from FY 2019). Profit margin: 6.5% (down from 7.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
分析記事 • Feb 11Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend YieldToday we'll take a closer look at Antibiotice S.A. ( BVB:ATB ) from a dividend investor's perspective. Owning a strong...
Is New 90 Day High Low • Jan 27New 90-day high: RON0.52The company is up 4.0% from its price of RON0.49 on 29 October 2020. The Romanian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
分析記事 • Jan 12Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)Does the January share price for Antibiotice S.A. ( BVB:ATB ) reflect what it's really worth? Today, we will estimate...
分析記事 • Dec 16Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?Broadly speaking, profitable businesses are less risky than unprofitable ones. Having said that, sometimes statutory...
分析記事 • Nov 24Is Antibiotice (BVB:ATB) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Nov 20New 90-day low: RON0.49The company is down 9.0% from its price of RON0.54 on 21 August 2020. The Romanian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: RON0.002 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: RON87.6m (up 23% from 3Q 2019). Net loss: RON1.10m (loss widened 46% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.
Is New 90 Day High Low • Sep 18New 90-day low: RON0.52The company is down 3.0% from its price of RON0.53 on 19 June 2020. The Romanian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period.